The user has been using finasteride for 3 years with good results and wants to switch to dutasteride combined with tamsulosin. They are seeking more information about tamsulosin.
Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.
A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.
TDM-105795 showed promising hair growth results, with higher efficacy than placebo and minimal side effects. It activates dormant hair follicle stem cells and may maintain gains without immediate loss, unlike minoxidil.
A Phase II clinical trial for TDM-105795 has started recruiting in the US, and it might be a promising treatment for hair loss. Many hair loss drugs, including this one, originate from China.
The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.
TDM-105795 showed better efficacy and safety in trials for hair loss, with a higher hair count improvement compared to GT20029 and HMI 115, but it's not as widely discussed. The user is questioning why this is the case.
TDM-105795 is a potential hair growth stimulant that works differently from minoxidil and could be used alongside it for enhanced growth. It completed phase 2 trials in 2024, with a medium to high chance of release in 2026, but lacks recent updates or phase 3 trial information.
A new hair loss treatment called TDM-105795 is discussed as a potential replacement or add-on to Minoxidil. Users express hope for new effective treatments.
The conversation is about using a product containing dutasteride and tamsulosin for hair loss. Users discuss separating the components and potential side effects like frequent urination and changes in libido.
A 19-year-old transgender individual is experiencing worsening temple recession despite taking female hormones and 1.25mg finasteride. They are seeking advice on additional treatments to address hair loss.
The conversation discusses an interview with Dr. Tsuji about hair follicle stem cell multiplication and the financial challenges of starting human clinical trials. It also mentions the need for funding to secure a patent for a protein that promotes hair growth.
HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.
The conversation discusses HMI-115, a potential cure for hair loss. Users share mixed opinions, with some expressing skepticism and others sharing anecdotal evidence of its effectiveness, including photos of significant hair regrowth from a trial participant.
The conversation is about a user's hair loss treatment regimen, which includes Dutasteride, oral Minoxidil, topical Dutasteride, Minoxidil sulfate, antioxidants, and various supplements. The user is also using a derma stamp and has paused Tretinoin due to a TCA peel recovery.
The conversation is about hair loss treatment progress using a combination of 0.1% finasteride, 0.025% tretinoin solution, and 2.5mg oral minoxidil. Users express positive reactions and hope for similar results.
Tocotrienols are being discussed as a potential treatment for hair regrowth, but users report no noticeable effects after several months of use. Some users are combining tocotrienols with other treatments like pumpkin seed oil and peppermint and rosemary oil.
The conversation discusses using T3 (triiodothyronine) as a topical treatment for hair growth, with some users noting it showed promising results in studies but lacked follow-up. Users express interest in trying T3 due to its potential effectiveness compared to Minoxidil.
Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.
A user discusses using tazarotene to enhance minoxidil's effectiveness for hair regrowth, believing it will make a significant difference. Others caution about potential risks of retinoids accelerating hair loss in some individuals.
Taurine shows potential in combating hair loss caused by chemical stress, especially when combined with other treatments like finasteride. Finasteride demonstrated better stress-reducing effects in the study.
GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.
The conversation discusses using shou wu chih or fo-ti/he shou wu for hair loss, with OP noticing stiffer beard and body hair. A user warns about potential liver damage from fo-ti and questions the effectiveness of alternative medicine.
Adding tretinoin can enhance the effectiveness of minoxidil by increasing sulfotransferase levels, making it beneficial for hair growth. However, it may not be necessary if using oral minoxidil.
Hair loss concerns and treatments like Minoxidil and Finasteride are humorously discussed. The community's quirks and dedication to battling hair loss are highlighted.
TGF-B affects hair growth, both causing stem cell division and death depending on amounts. Amplifica's treatment injects Scube3 to increase TGF-B for hair growth.